Aktienanalyse zu Tempest Therapeutics Inc (TPST)TPSTTempest Therapeutics Inc

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company moving towards late-stage development with a portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class to treat a range of cancers. Its programs range from early research to the lead program, amezalpat, a pivotal study in first-line hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, is a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (PGE2), a pathway implicated in multiple cancers. Its development strategy for TPST-1495 includes evaluation in familial adenomatous polyposis (FAP), a rare genetic disorder that increases the risk of gastrointestinal cancers. Its pipeline also includes TPST-2003, TPST-2206, TPST-3003, and TPST-3206. TPST-2003 is a new dual-targeting CD19/BCMA CAR-T asset. TPST-2206 is a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma. TPST-3206 is an allogeneic dual-targeting CD70/CD70. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Tempest Therapeutics Inc is not a good buy right now due to its ongoing financial losses and cash flow issues. The current price is $1.06, with a year-to-date change of -64.07%, indicating significant underperformance. Although the recent quarterly loss improved to -$5.2 million, the company ended Q2 with only $1.7 million in cash, raising concerns about liquidity. The RSI is at 47.458, suggesting a neutral momentum, and the forward P/E ratio is currently not applicable due to negative earnings. The main risk is the company's declining cash reserves, which could hinder operational capabilities.